Krilogy Financial LLC Has $1.99 Million Stake in Repligen Corporation $RGEN

Krilogy Financial LLC trimmed its position in shares of Repligen Corporation (NASDAQ:RGEN) by 32.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 13,662 shares of the biotechnology company’s stock after selling 6,539 shares during the quarter. Krilogy Financial LLC’s holdings in Repligen were worth $1,992,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its position in shares of Repligen by 1.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after buying an additional 75 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Repligen by 1.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 80 shares in the last quarter. Drive Wealth Management LLC lifted its stake in Repligen by 2.5% in the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 93 shares in the last quarter. Hilltop National Bank boosted its position in Repligen by 8.0% during the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after acquiring an additional 95 shares during the period. Finally, ProShare Advisors LLC grew its stake in Repligen by 4.3% during the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $139.40 on Thursday. The firm has a market cap of $7.85 billion, a price-to-earnings ratio of 6,973.49, a price-to-earnings-growth ratio of 2.61 and a beta of 1.13. The company’s fifty day moving average is $160.47 and its 200-day moving average is $145.51. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77.

Insider Activity

In other Repligen news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karen A. Dawes sold 275 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. This represents a 0.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 4,657 shares of company stock worth $706,877. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RGEN. Wells Fargo & Company increased their price target on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. Canaccord Genuity Group boosted their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen raised shares of Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.